Atea Pharmaceuticals Inc. has outlined its key strategic priorities for 2026, focusing on the advancement and diversification of its antiviral pipeline. The company plans to continue disciplined execution and resource allocation to maximize clinical and commercial potential. Atea will advance its lead Hepatitis C virus (HCV) program, with topline results from two global Phase 3 trials—C-BEYOND in North America and C-FORWARD outside North America—expected in mid and late 2026, respectively. The company also intends to initiate a first-in-human Phase 1 clinical program for its Hepatitis E virus (HEV) product candidate, AT-587, by mid-2026. Atea will assess potential strategic transactions and global commercialization opportunities as it approaches these key development milestones. The company remains committed to expanding its antiviral portfolio to address unmet medical needs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9621885) on January 08, 2026, and is solely responsible for the information contained therein.